The Merxin device platforms are based on popular and successful original devices designed for combination products (device+formulation) of mono, duo and triple drug formulations. Our devices are perfectly suited for new molecules, and they are available for clinical trials and commercial launch.
MRX001 is a substitutable (AB rated) generic multidose blister dry powder inhaler for fluticasone + salmeterol DPI.
MRX002 is a clear PET vial that can be fitted with pMDI valves to visualise formulations and act as a dose indicator.
MRX003 is a substitutable (AB rated) generic capsule inhaler for tiotropium DPI.
MRX004 is a substitutable (AB rated) generic fine soft mist inhaler for tiotropium or/and olodaterol.